Page 468 - An Evidence Review of Active Surveillance in Men With Localized Prostate Cancer
P. 468

Appendix Table C4.1. Descriptive characteristics of the randomized controlled trials and comparative cohort studies considered
                                        relevant to KQ4 (continued)
                                        Author, Year      Study name       Comparison       Study          Sample          Inclusion criteria                  Population description:             Quality
                                        [Pubmed ID]       /Database                         duration       size (total)                                        Age                                 Comments
                                                                                                                                                               PSA (ng/mL)
                                        Study design                                                                                                           Tumor grade
                                                                                                                                                               Stage
                                        Berge 231         SEER-            WW vs. RP        1991-92        12,711          cT1-2 or pT1-3, age ≥65,            Median age: WW, 77; RP, 70;         C
                                        2007              Medicare         vs. RT vs.                                      continuously enrolled on            RT, 74
                                                                                a
                                        17178188                           ADT              5 yr                           Medicare for the entire study
                                                                                                                           period. Excluded patients           PSA: NR
                                        Retrospective                                                                      enrolled in an HMO, those with
                                        cohort                                                                             primary treatment discrepancy       Grade: WW, well dif., 40.2%;
                                                                                                                           between SEER and Medicare           moderately dif., 40.8%; poorly
                                                                                                                           data, those who died before the     dif., 10.3%; undiff, 0.6%;
                                                                                                                           end of the study period, patients   unknown, 8.2%. RP, well dif.,
                                                                                                                           with metastatic disease, and        10.2%; moderately dif., 67.6%;
                                                                                                                           those with tumors clinically        poorly dif., 20.5%; undiff, 0.5%;
                                                                                                                           classified as extension through     unknown, 1.2%. RT, well dif.,
                                                                                                                           capsule or with positive lymph      20.5%; moderately dif., 58.1%;
                                                                                                                           nodes (only for the non-RP          poorly dif., 15.7%; undiff, 0.6%;
                                                                                                                           groups).                            unknown, 5.0%.

                                                                                                                           Patients with pT3 tumors were       Stage: WW, In situ, 0.9%; T1/2,
                                                                                                                           included only in the surgical arm   99.1; pT3, 0%. RP, In situ, 0.1;
                                                                                                                           to account for the lack of          T1/2, 54.6; pT3, 45.4%. RT, In
                                                                                                                           pathologic staging in patients      situ, 0%; T1/2, 100%; pT3, 0%.
                                                                                                                           receiving other treatments.
                                        Elliott 218       CaPSURE          (RP,             Median         6597            Newly diagnosed with prostate       Age: <60 yr, 25%; 60-59, 40%;       B
                                        2007                               RP+EBRT,         2.7 yr                         cancer between 1995 and 2006        ≥70 yr, 35%
                                        17570425                           cryotherapy,     (range 3                       with complete diagnostic and
                                                                           BT,              days to                        treatment clinical data available,   PSA: ≤4, 14%; 4.1-10.0, 62%;
                                        Retrospective                      BT+EBRT,         10.9 yr)                       and without a history of urethral   10.1-20.0, 16%; >20, 8%
                                        cohort                             EBRT, or                                        stricture
                                                                           hormones)                                                                           Gleason score: 2-6, 65%; 7,
                                                                           vs. WW                                                                              26%; 8-10, 9%

                                                                                                                                                               Stage: T1, 53%; T2, 45%; T3a,
                                                                                                                                                               2%



                                        a  We did not extract data from the group of patients receiving primary ADT as the only initial therapy.




                                                                                                                        C-152
   463   464   465   466   467   468   469   470   471   472   473